Patent Invalidation in Basel

Patent invalidation Basel strategy follows a rulebook that stops at the Swiss border, because Switzerland sits outside the European Union and therefore outside the Unitary Patent and the Unified Patent Court. Swiss rights and the Swiss parts of European patents are decided instead by a single specialised national court that hears validity and infringement in the same proceedings. For a city that hosts the headquarters of Roche and Novartis and roughly 800 life-science companies, that combination makes Swiss invalidity work its own discipline. PerspireIP builds nullity-grade prior-art and invalidity searches for generic entrants, biosimilar developers, medtech manufacturers and accused infringers operating out of the Basel region.

Why patent invalidation Basel strategy starts outside the UPC

The Unitary Patent and the Unified Patent Court are European Union instruments, open only to EU member states. Switzerland is a contracting state of the European Patent Convention but not an EU member, so — like the United Kingdom and Norway — it cannot join the UPC Agreement or elect the court’s jurisdiction. A Unitary Patent therefore has no effect in Switzerland at all, and a European patent must still be validated, maintained and enforced here separately.

The practical consequence catches out many multinational teams. A revocation action won at the UPC clears the participating EU states, but it does not touch the Swiss part of the same European patent, which stays under the exclusive competence of the Swiss Federal Patent Court. A Basel manufacturer can win in Munich or Paris and still face an injunction covering its home market. The reverse is equally true: a Swiss-only attack does nothing for your EU exposure.

So Swiss invalidity has to be planned as its own track, running alongside — not inside — any European campaign.

One more territorial quirk matters when you scope an action. Switzerland and Liechtenstein form a single unitary patent territory, so a Swiss patent — and the Swiss designation of a European patent — takes effect across both states, and the Federal Patent Court’s exclusive competence extends to that combined territory. Clearing Switzerland therefore clears Liechtenstein in the same action, which is worth confirming before you scope any European campaign.

• Map which family members are validated in Switzerland and which sit in the UPC system
• Confirm whether a Swiss national patent, a validated European patent, or both are asserted
• Plan the Swiss action on its own timetable, because no EU forum can resolve it
• Keep one evidence base so the same prior art serves both fronts

The Swiss Federal Patent Court hears validity and infringement together

Switzerland concentrates patent litigation in one venue. The Federal Patent Court (Bundespatentgericht / Tribunal fédéral des brevets), seated in St. Gallen, has exclusive competence over civil validity and infringement disputes, licence actions, preliminary measures and enforcement of its own decisions. It began work in 2012, taking jurisdiction away from 26 separate cantonal courts, and its panels combine legally qualified judges with technically qualified judges drawn from the relevant field of science or engineering.

Crucially, the same court examines infringement and validity in the same proceedings. If you are sued for infringement in Switzerland you can attack the patent by counterclaim or as a defence, and one panel decides both. That is the opposite of the German model, where a regional court rules on infringement while the Federal Patent Court in Munich decides nullity separately. Switzerland has no bifurcation, and therefore no injunction gap: you cannot be enjoined by one court while a second court is still deciding whether the patent should ever have been granted.

Two further features shape how a Basel case is run. Appeals go to the Swiss Federal Supreme Court, which decides points of law only and has no technically qualified judges, so the technical record built at first instance is effectively your one opportunity to be believed on the science. And under Article 36(3) of the Patent Court Act, briefs and proceedings can be conducted in English where the parties and the court agree — a real convenience for the international teams that run IP out of Basel.

Basel’s pharma cluster and what actually gets attacked

Basel is the densest life-sciences cluster in Europe. Two of the world’s largest pharmaceutical companies, Roche and Novartis, are headquartered in the city; Lonza, Bayer, Syngenta and Moderna hold headquarters or major group functions in the region; and around 800 life-science companies now operate there, supported by the University of Basel and the Friedrich Miescher Institute for Biomedical Research. The city sits on the tri-border corner where Switzerland meets France and Germany, so supply chains and litigation exposure routinely straddle three jurisdictions.

That profile determines what invalidity work looks like here. The patents that decide market entry are rarely the original molecule claims — those have usually expired. The fight is over the secondary layer built around them, and each type demands a different kind of prior art.

• Second-medical-use claims, including the Swiss-type format the EPO Enlarged Board allowed in G 5/83 in December 1984
• Polymorphs, salts, hydrates and other solid-state forms
• Formulations, dosage regimens and combination products
• Biologics, manufacturing processes and purification steps
• Device and delivery claims on injectors, inhalers and diagnostics

Killing these claims usually turns on non-patent literature rather than patents: conference abstracts and posters, clinical-trial registry entries, pharmacopoeia monographs, product labels, published regulatory material, doctoral theses and prior public use. A chemistry-literate search that reaches those sources is worth far more in Basel than a larger pile of patent hits.

Supplementary protection certificates and the end-of-lifecycle attack

Swiss exclusivity rarely ends when the patent term does. Under Article 140b of the Swiss Patents Act, a supplementary protection certificate can extend protection for a medicinal product by up to five years where the product, a process for making it, or a use of it is protected by a patent and a Swiss marketing authorisation has been granted. Since 1 January 2019 a Swiss SPC can be extended by a further six months on the strength of an agreed paediatric investigation plan, and stand-alone paediatric certificates are available for patents that never had an SPC.

For a generic or biosimilar entrant that changes the arithmetic completely. The certificate is built on a basic patent, so the validity of that patent is the first thing any serious launch analysis tests, and the Swissreg SPC and paediatric-SPC register published by the Swiss Federal Institute of Intellectual Property is where the real Swiss expiry dates are mapped — not the nominal patent term.

Timing recently improved. On 9 December 2025 the Federal Patent Court announced that nullity actions will be expedited whenever the challenged patent underlies a pending infringement action, targeting a decision within a maximum of 12 months by dropping the instruction hearing and sharply restricting deadline extensions. That removes roughly six months from a timeline that had been running around a year and a half, and the practice applies immediately, including to already-pending cases. For patent invalidation Basel launch planning, that means a nullity action filed early enough can now realistically conclude before an SPC expires rather than after it.

Swiss national patents are granted without a novelty examination

Here is the fact that most surprises companies arriving from the United States or the EPO system. The Swiss Federal Institute of Intellectual Property does not examine national Swiss patent applications ex officio for novelty and inventive step. Its examination is partial and substantive only as to other legal requirements, which means a Swiss patent can be granted, published and asserted even though the claimed invention was never new or never inventive.

The burden of testing novelty is therefore pushed onto the courts, and onto whoever is defending against the patent. Article 26 of the Patents Act lets any person with a proven interest bring an invalidity action where the invention is excluded from patentability, is not novel, is obvious, is insufficiently disclosed for a skilled person to carry it out, or where the application was unduly amended. Against an unexamined right, a rigorous prior-art search does the job the office never did.

This is changing, but slowly. From 1 January 2027 the Institute will run a mandatory fee-based prior-art search on every application and publish the report on Swissreg, and applicants will be able to request a full substantive examination covering novelty and inventive step for an additional fee; pending applications can opt into the new regime until 1 April 2027. The reform is prospective, so the large existing stock of unexamined Swiss patents stays in force for years. For anyone facing one of them, invalidity searching remains unusually high-yield.

EPO opposition, Swiss nullity, or both

Where a European patent is involved, Basel companies usually have two genuine routes, and the choice is driven by the calendar. An opposition filed at the European Patent Office within nine months of grant is a central attack on the patent as granted, and unlike a UPC revocation action it reaches the Swiss part along with every other designated state. For a patent still inside that window, opposition is often the most efficient single strike available.

Once the nine months have passed, the only way to clear the Swiss part is a nullity action at the Federal Patent Court. The two routes can also run in parallel, and because the Swiss court weighs inventive step in a way closely informed by the EPO’s problem-and-solution approach, a well-built record supports both without duplication. The Swiss Federal Supreme Court has itself followed EPO Board of Appeal reasoning on questions such as singling out from a disclosure.

Sequencing is the part teams most often get wrong. Opposition is centrally efficient but slow, and an opposition still pending does not by itself stop a Swiss infringement action from proceeding. If a Basel product is already on the market or a launch date is fixed, the Swiss nullity route usually has to be planned on its own timetable rather than parked behind the EPO. We scope both timelines side by side at the outset so the decision is made on evidence rather than on whichever deadline arrives first.

We build one evidence base sized to whichever combination you and your Swiss counsel choose, so that positions stay consistent across forums, cost is not spent twice, and you can pivot as opposition and litigation timelines move.

How PerspireIP builds a Swiss nullity-grade search

Every patent invalidation Basel project starts the same way: we map the asserted claims element by element, identify the priority date that actually governs each one, and then search against that date rather than against the filing date on the cover page. From there the searching runs across global patent literature and, critically for pharmaceutical and chemical subject matter, across the non-patent sources where the decisive disclosure usually lives.

• Claim charting aligned to Article 26 grounds and the EPO problem-and-solution approach
• Structure, Markush, sequence and reaction searching for chemistry and biologics claims
• Clinical-trial registries, conference abstracts, pharmacopoeias, labels and regulatory disclosures
• German, French and Italian language art, which national searches routinely miss
• A written invalidity opinion plus reference packages ready for the Federal Patent Court or EPO opposition

The deliverable is a record a technically qualified Swiss judge can follow, not a raw hit list. That matters more here than almost anywhere, because the technical merits are settled at first instance and the Federal Supreme Court will only review the law. We work alongside your Swiss patent attorneys and litigators as a specialist search partner, deliver to court deadlines, and keep every engagement confidential — whether the assignment is a single freedom-to-operate blocker, an SPC-driven launch analysis, or a portfolio-wide campaign run from Basel across three borders.

IP Landscape & Resources in Basel

Key intellectual-property authorities and venues relevant to Basel:

• Swiss Federal Institute of Intellectual Property (IPI) — Switzerland's national IP office; grants Swiss patents and SPCs and publishes the Swissreg registers
• Swiss Federal Patent Court — the St. Gallen court with exclusive competence over Swiss validity and infringement disputes
• Swiss Federal Supreme Court — hears appeals from the Federal Patent Court on points of law
• European Patent Office (EPO) — grants European patents validated in Switzerland and hears nine-month post-grant oppositions

Request a Patent Invalidation Search in Basel

Explore related PerspireIP services: Patent Invalidation · Prior Art Litigation Search · Patent Infringement Analysis.

Frequently Asked Questions